Effect of Metformin Treatment on Insulin Resistance Markers, and Circulating Irisin in Women with Polycystic Ovarian Syndrome (PCOS)

Abstract

Polycystic ovarian syndrome (PCOS) is considered as a common endocrinal dysfunction among adult women characterized by polycystic ovaries, anovulation, and hyperandrogenism. Irisin is associated with metabolic parameters and insulin resistance. However, the association of irisin with PCOS remains poorly delineated. This study was aimed to examine circulating irisin levels and effects of metformin on this parameter in women with PCOS. Moreover, the association of irisin with insulin resistance markers was determined. Thirty-nine females with PCOS, aged 20–40 years, participated in this study and received 500 mg of metformin once daily for 3 months. Serum creatinine, blood urea nitrogen, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein (LDL), cholesterol, triglyceride, fasting blood sugar, testosterone, 17-hydroxyprogesterone, and irisin were assayed in the studied groups. Circulating irisin was significantly higher in PCOS women. Circulating irisin levels correlated with 17-hydroxyprogesterone, testosterone, and insulin. Three months metformin treatment decreased circulating irisin in PCOS women and improved IR. Circulating irisin is directly associated with insulin resistance in PCOS women and may be used as a biomarker for IR in these patients. Moreover, metformin as a confounding therapy in metabolic diseases can be used to regulate circulating irisin levels in PCOS women.

Key words

polycystic ovarian syndrome - insulin resistance - irisin

• References

• 1 Teede H, Deeks A, Moran L. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010; 8: 41
• 2 Ndefo UA, Eaton A, Green MR. Polycystic ovary syndrome: A review of treatment options with a focus on pharmacological approaches. P T. 2013; 38: 336-355
• 3 Ding T, Hardiman PJ, Petersen I. et al. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: A systematic review and meta-analysis. Oncotarget 2017; 8: 96351-96358
• 4 Baldani DP, Skrgatic L, Ougouag R. Polycystic ovary syndrome: Important underrecognised cardiometabolic risk factor in reproductive-age women. Int J Endocrinol 2015; 786362
• 5 Moran C, Arriaga M, Rodriguez G et al. Obesity differentially affects phenotypes of polycystic ovary syndrome. Women. Int J Endocrinol 2012; 317241
• 6 Polak K, Czyzyk A, Simoncini T. et al. New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest 2017; 40: 1-8
• 7 Aydin S, Kuloglu T, Aydin S. et al. Skeletal muscle and serum irisin responses to with or without water exercise in young and old male rats: Cardiac muscle produces more irisin than skeletal muscle. Peptides 2014; 52: 68-73
• 8 Bostrom P, Wu J, Jedrychowski MP. et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463-468
• 9 Aydin S, Aydin S. Irisin Concentrations as a Myocardial Biomarker. In Patel VB, Preedy VR. editors Biomarkers in Cardiovascular Disease. Berlin: Springer; 2016: 1-16
• 10 Shanaki M, Moradi N, Emamgholipour S. et al. Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes. Diabetes. Metab Syndr 2017; Suppl 1 S467-S472. doi:10.1016/j.dsx.2017.03.037 [Epub 2017 Mar 31]
• 11 Hee Park K, Zaichenko L, Brinkoetter M. et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 2013; 98: 4899-4907
• 12 Lee HJ, Lee JO, Kim N. et al. Irisin, a novel myokine, regulates glucose uptake in skeletal muscle cells via AMPK. Mol Endocrinol 2015; 29: 873-881
• 13 Choi YK, Kim MK, Bae KH. et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013; 100: 96-101
• 14 Kuzmicki M, Telejko B, Lipinska D. et al. Serum irisin concentration in women with gestational diabetes. Gynecol Endocrinol 2014; 30: 636-639
• 15 Moreno-Navarrete JM, Ortega F, Serrano M. et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013; 98: E769-E778
• 16 Oelmann S, Nauck M, Völzke H. et al. circulating irisin concentrations are associated with a favourable lipid profile in the general population. PLoS One 2016; 11: e0154319
• 17 Li M, Yang M, Zhou X. et al. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2015; 100: 1485-1493
• 18 Bostancı MS, Akdemir N, Cinemre B. et al. Serum irisin levels in patients with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci 2015; 19: 4462-4468
• 19 Wang C, Zhang XY, Sun Y. et al. Higher circulating irisin levels in patients with polycystic ovary syndrome:a meta-analysis. Gynecol Endocrinol 2018; 34: 290-293
• 20 Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47
• 21 Adamska A, Karczewska-Kupczewska M, Lebkowska A. et al. Serum irisin and its regulation by hyperinsulinemia in women with polycystic ovary syndrome. Endocr J 2016; 63: 1107-1112
• 22 Gruszka A. New Insight into the mechanisms of the anti-hyperglycemic action of metformin. Br J Med Med Res 2016; 13: 1-9
• 23 Lee P, Linderman JD, Smith S. et al. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab 2014; 19: 302-309
• 24 Chen JQ, Huang YY, Gusdon AM. et al. Irisin: A new molecular marker and target in metabolic disorder. Lipids Health Dis 2015; 14: 2
• 25 Tang H, Yu R, Liu S. et al. Irisin inhibits hepatic cholesterol synthesis via ampk-srebp2 signaling. Ebio Med 2016; 6: 139-148
• 26 de la Iglesia R, Lopez-Legarrea P, Crujeiras AB. et al. Irisin depletion under energy restriction is associated with improvements in lipid profile in metabolic syndrome patients. Clin Endocrinol (Oxf) 2014; 81: 306-311
• 27 Garcés MF, Peralta JJ, Ruiz-Linares CE. et al. Irisin levels during pregnancy and changes associated with the development of preeclampsia. J Clin Endocrinol Metab 2014; 99: 2113-2119
• 28 Sesti G, Andreozzi F, Fiorentino TV. et al. High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetol 2014; 51: 705-713
• 29 Polyzos SA, Kountouras J, Shields K. et al. Irisin: a renaissance in metabolism?. Metabolism 2013; 62: 1037-1044
• 30 Yildiz N, Calan M, Cobanoglu M. et al. The association between increased circulating irisin levels and inflammatory markers in polycystic ovary syndrome. Endocr Abst 2016;
• 31 Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327: 951
• 32 Dumitrescu R, Mehedintu C, Briceag I. et al. Metformin-Clinical Pharmacology in PCOs. J Med Life 2015; 8: 187-192
• 33 Lashen H. Role of metformin in the management of polycystic ovary syndrome. Ther Adv Endocrinol Metab 2010; 1: 117-128
• 34 Olszanecka-Glinianowicz M, Banaś M, Zahorska-Markiewicz B. et al. Insulin resistance and serum concentrations of ovarian and adrenal androgen in obese women without additional disease and with polycystic ovary syndrome. Endokrynol Polska 2005; 56: 921-926